scholarly journals Automatic discovery of transferable patterns in protein-ligand interaction networks

Author(s):  
Aida Mrzic ◽  
Dries Van Rompaey ◽  
Stefan Naulaerts ◽  
Hans De Winter ◽  
Wim Vanden Berghe ◽  
...  

In recent years, the pharmaceutical industry has been confronted with rising R&D costs paired with decreasing productivity. Attrition rates for new molecules are tremendous, with a substantial number of molecules failing in an advanced stage of development. Repositioning previously approved drugs for new indications can mitigate these issues by reducing both risk and cost of development. Computational methods have been developed to allow for the prediction of drug-target interactions, but it remains difficult to branch out into new areas of application where information is scarce. Here, we present a proof-of-concept for discovering patterns in protein-ligand data using frequent itemset mining. Two key advantages of our method are the transferability of our patterns to different application domains and the facile interpretation of our recommendations. Starting from a set of known protein-ligand relationships, we identify patterns of molecular substructures and protein domains that lie at the basis of these interactions. We show that these same patterns also underpin metabolic pathways in humans. We further demonstrate how association rules mined from human protein-ligand interaction patterns can be used to predict antibiotics susceptible to bacterial resistance mechanisms.

2018 ◽  
Author(s):  
Aida Mrzic ◽  
Dries Van Rompaey ◽  
Stefan Naulaerts ◽  
Hans De Winter ◽  
Wim Vanden Berghe ◽  
...  

In recent years, the pharmaceutical industry has been confronted with rising R&D costs paired with decreasing productivity. Attrition rates for new molecules are tremendous, with a substantial number of molecules failing in an advanced stage of development. Repositioning previously approved drugs for new indications can mitigate these issues by reducing both risk and cost of development. Computational methods have been developed to allow for the prediction of drug-target interactions, but it remains difficult to branch out into new areas of application where information is scarce. Here, we present a proof-of-concept for discovering patterns in protein-ligand data using frequent itemset mining. Two key advantages of our method are the transferability of our patterns to different application domains and the facile interpretation of our recommendations. Starting from a set of known protein-ligand relationships, we identify patterns of molecular substructures and protein domains that lie at the basis of these interactions. We show that these same patterns also underpin metabolic pathways in humans. We further demonstrate how association rules mined from human protein-ligand interaction patterns can be used to predict antibiotics susceptible to bacterial resistance mechanisms.


Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3193
Author(s):  
Christina Pfab ◽  
Luisa Schnobrich ◽  
Samir Eldnasoury ◽  
André Gessner ◽  
Nahed El-Najjar

The substantial costs of clinical trials, the lengthy timelines of new drug discovery and development, along the high attrition rates underscore the need for alternative strategies for finding quickly suitable therapeutics agents. Given that most approved drugs possess more than one target tightly linked to other diseases, it encourages promptly testing these drugs in patients. Over the past decades, this has led to considerable attention for drug repurposing, which relies on identifying new uses for approved or investigational drugs outside the scope of the original medical indication. The known safety of approved drugs minimizes the possibility of failure for adverse toxicology, making them attractive de-risked compounds for new applications with potentially lower overall development costs and shorter development timelines. This latter case is an exciting opportunity, specifically in oncology, due to increased resistance towards the current therapies. Indeed, a large body of evidence shows that a wealth of non-cancer drugs has beneficial effects against cancer. Interestingly, 335 drugs are currently being evaluated in different clinical trials for their potential activities against various cancers (Redo database). This review aims to provide an extensive discussion about the anti-cancer activities exerted by antimicrobial agents and presents information about their mechanism(s) of action and stage of development/evaluation.


2020 ◽  
Author(s):  
Ben Geoffrey A S ◽  
Pavan Preetham Valluri ◽  
Akhil Sanker ◽  
Rafal Madaj ◽  
Host Antony Davidd ◽  
...  

<p>Network data is composed of nodes and edges. Successful application of machine learning/deep learning algorithms on network data to make node classification and link prediction has been shown in the area of social networks through which highly customized suggestions are offered to social network users. Similarly one can attempt the use of machine learning/deep learning algorithms on biological network data to generate predictions of scientific usefulness. In the present work, compound-drug target interaction data set from bindingDB has been used to train machine learning/deep learning algorithms which are used to predict the drug targets for any PubChem compound queried by the user. The user is required to input the PubChem Compound ID (CID) of the compound the user wishes to gain information about its predicted biological activity and the tool outputs the RCSB PDB IDs of the predicted drug target. The tool also incorporates a feature to perform automated <i>In Silico</i> modelling for the compounds and the predicted drug targets to uncover their protein-ligand interaction profiles. The programs fetches the structures of the compound and the predicted drug targets, prepares them for molecular docking using standard AutoDock Scripts that are part of MGLtools and performs molecular docking, protein-ligand interaction profiling of the targets and the compound and stores the visualized results in the working folder of the user. The program is hosted, supported and maintained at the following GitHub repository </p> <p><a href="https://github.com/bengeof/Compound2Drug">https://github.com/bengeof/Compound2Drug</a></p>


Author(s):  
Charles A. Santana ◽  
Fabio R. Cerqueira ◽  
Carlos H. Da Silveira ◽  
Alexandre V. Fassio ◽  
Raquel C. De Melo-Minardi ◽  
...  

2020 ◽  
Vol 21 (12) ◽  
pp. 4270 ◽  
Author(s):  
Alfredo Juárez-Saldivar ◽  
Michael Schroeder ◽  
Sebastian Salentin ◽  
V. Joachim Haupt ◽  
Emma Saavedra ◽  
...  

Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects nearly eight million people worldwide. There are currently only limited treatment options, which cause several side effects and have drug resistance. Thus, there is a great need for a novel, improved Chagas treatment. Bifunctional enzyme dihydrofolate reductase-thymidylate synthase (DHFR-TS) has emerged as a promising pharmacological target. Moreover, some human dihydrofolate reductase (HsDHFR) inhibitors such as trimetrexate also inhibit T. cruzi DHFR-TS (TcDHFR-TS). These compounds serve as a starting point and a reference in a screening campaign to search for new TcDHFR-TS inhibitors. In this paper, a novel virtual screening approach was developed that combines classical docking with protein-ligand interaction profiling to identify drug repositioning opportunities against T. cruzi infection. In this approach, some food and drug administration (FDA)-approved drugs that were predicted to bind with high affinity to TcDHFR-TS and whose predicted molecular interactions are conserved among known inhibitors were selected. Overall, ten putative TcDHFR-TS inhibitors were identified. These exhibited a similar interaction profile and a higher computed binding affinity, compared to trimetrexate. Nilotinib, glipizide, glyburide and gliquidone were tested on T. cruzi epimastigotes and showed growth inhibitory activity in the micromolar range. Therefore, these compounds could lead to the development of new treatment options for Chagas disease.


2020 ◽  
Author(s):  
Ben Geoffrey A S ◽  
Pavan Preetham Valluri ◽  
Akhil Sanker ◽  
Rafal Madaj ◽  
Host Antony Davidd ◽  
...  

<p>Network data is composed of nodes and edges. Successful application of machine learning/deep learning algorithms on network data to make node classification and link prediction has been shown in the area of social networks through which highly customized suggestions are offered to social network users. Similarly one can attempt the use of machine learning/deep learning algorithms on biological network data to generate predictions of scientific usefulness. In the present work, compound-drug target interaction data set from bindingDB has been used to train machine learning/deep learning algorithms which are used to predict the drug targets for any PubChem compound queried by the user. The user is required to input the PubChem Compound ID (CID) of the compound the user wishes to gain information about its predicted biological activity and the tool outputs the RCSB PDB IDs of the predicted drug target. The tool also incorporates a feature to perform automated <i>In Silico</i> modelling for the compounds and the predicted drug targets to uncover their protein-ligand interaction profiles. The programs fetches the structures of the compound and the predicted drug targets, prepares them for molecular docking using standard AutoDock Scripts that are part of MGLtools and performs molecular docking, protein-ligand interaction profiling of the targets and the compound and stores the visualized results in the working folder of the user. The program is hosted, supported and maintained at the following GitHub repository </p> <p><a href="https://github.com/bengeof/Compound2Drug">https://github.com/bengeof/Compound2Drug</a></p>


2013 ◽  
Vol 53 (3) ◽  
pp. 623-637 ◽  
Author(s):  
Jérémy Desaphy ◽  
Eric Raimbaud ◽  
Pierre Ducrot ◽  
Didier Rognan

2020 ◽  
Vol 21 (10) ◽  
pp. 1011-1026
Author(s):  
Bruna O. Costa ◽  
Marlon H. Cardoso ◽  
Octávio L. Franco

: Aminoglycosides and β-lactams are the most commonly used antimicrobial agents in clinical practice. This occurs because they are capable of acting in the treatment of acute bacterial infections. However, the effectiveness of antibiotics has been constantly threatened due to bacterial pathogens producing resistance enzymes. Among them, the aminoglycoside-modifying enzymes (AMEs) and β-lactamase enzymes are the most frequently reported resistance mechanisms. AMEs can inactivate aminoglycosides by adding specific chemical molecules in the compound, whereas β-lactamases hydrolyze the β-lactams ring, preventing drug-target interaction. Thus, these enzymes provide a scenario of multidrug-resistance and a significant threat to public health at a global level. In response to this challenge, in recent decades, several studies have focused on the development of inhibitors that can restore aminoglycosides and β-lactams activity. In this context, peptides appear as a promising approach in the field of inhibitors for future antibacterial therapies, as multiresistant bacteria may be susceptible to these molecules. Therefore, this review focused on the most recent findings related to peptide-based inhibitors that act on AMEs and β-lactamases, and how these molecules could be used for future treatment strategies.


Author(s):  
Xiaodong Pang ◽  
Linxiang Zhou ◽  
Lily Zhang ◽  
Lina Xu ◽  
Xinyi Zhang

Sign in / Sign up

Export Citation Format

Share Document